Launching novel oncology therapies in Asia: Identifying and communicating value
Novel cancer therapies are offering patients new treatments and better outcomes worldwide. Recent changes in healthcare policies across APAC have reignited interest in the region as a strong market for oncology, such as China's fast tracking approval of therapies for severe and rare diseases and Vietnam's plan to cover health insurance for 80% of the population. Unfortunately, the often eye-watering costs of these new therapies means that, currently, for the many patients who still have to pay for treatment out of pocket, novel therapies are beyong reach. Pharma brands need to demonstate clear value if they want to achieve success.
Pharma China Annual Forum 2017
We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China.
We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China. Representing Research Partnership will be Asia Pacific Director and emerging markets specialist Pei Li Teh, who will be presenting the paper ’Urban China’s Evolving Patient Journey’ from 14:30 – 15:00.
Understanding the chronic disease patient journey in emerging markets
In this paper, we explore the chronic disease patient journey in emerging markets and provide you with the insights you require to identify the key inflection points in these rapidly changing and diverse regions.
With growing urban populations and increasing purchasing power, emerging markets remain an attractive prospect for growth. A high proportion of the urban emerging market population already suffers from chronic diseases and prevalence is set to further increase as lifestyles become closer to those in the West. The chronic disease patient is a critical stakeholder in emerging markets because they often have to pay for their healthcare out of pocket. Moreover, these markets often don’t have formal primary care systems, so the patient is the only constant in the journey. Understanding their journey is critical in order to best leverage these potential new markets.
How an understanding of the patient journey and addiction treatment pathways helped support brand uptake
Our client had previously conducted some research and knew that a large proportion of target patients also had addiction issues. They wanted to know more about addiction treatment pathways and the issues that this large proportion of their customers and potential HCP treaters were facing. Therefore, they were seeking further insights to gain a 360 degree understanding to better serve their customers needs.
How multi-stakeholder patient journey insights in oncology were brought to life with creative outputs and data visualisation
Two clients were co-developing a product and needed to understand the patient journey in two areas of oncology, in order to identify the leverage points where they could provide an improved patient experience.
We carried out qualitative research with all relevant stakeholders - patients, caregivers, oncologists, haematologists and nurses in all the markets in order to get a 360 degree view of the patient journey, triangulate different viewpoints and understand where disconnects existed between stakeholders.